Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus PROLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus PROLOPRIM.
COR-OTICIN vs PROLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Inhibits bacterial dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA, RNA, and protein synthesis.
1-2 drops in each affected ear twice daily for 7 days.
100 mg orally twice daily or 200 mg orally once daily.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is 8-10 hours in normal renal function; prolonged (>20 hours) in significant renal impairment.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal (80-90% as unchanged drug); less than 5% as metabolites; fecal excretion negligible.
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic